👉 Mehr Infos: www.itmp.fraunhofer.de/de/presse/pr...
#Forschung #Allergologie #Innovation #FraunhoferITMP #Biotech
👉 Mehr Infos: www.itmp.fraunhofer.de/de/presse/pr...
#Forschung #Allergologie #Innovation #FraunhoferITMP #Biotech
#RareDiseases #research #FraunhoferITMP @erdera.bsky.social @remedi4all.bsky.social
#RareDiseases #research #FraunhoferITMP @erdera.bsky.social @remedi4all.bsky.social
Our new MicroThera group at Fraunhofer ITMP in Frankfurt seeks a PhD candidate (all genders) to develop culture-based engraftment assays for microbiota therapies – embedded in clinical studies!
#PhD #Microbiome #FraunhoferITMP #FrankfurtJobs #ClinicalResearch
Our new MicroThera group at Fraunhofer ITMP in Frankfurt seeks a PhD candidate (all genders) to develop culture-based engraftment assays for microbiota therapies – embedded in clinical studies!
#PhD #Microbiome #FraunhoferITMP #FrankfurtJobs #ClinicalResearch
#Rheumatologie #TopMediziner #Medizin
#Rheumatologie #TopMediziner #Medizin
#Hamburg war erstmals Gastgeber der Top-Konferenz für Lab Automation & Screening. Unser Standortleiter Dr. Philip Gribbon eröffnete als SLAS-Präsident – wir sind stolz auf unser starkes Programm! 👏
#SLAS #FraunhoferITMP #labautomation #screening
#Hamburg war erstmals Gastgeber der Top-Konferenz für Lab Automation & Screening. Unser Standortleiter Dr. Philip Gribbon eröffnete als SLAS-Präsident – wir sind stolz auf unser starkes Programm! 👏
#SLAS #FraunhoferITMP #labautomation #screening
in Hamburg. Check out our short video!
tinyurl.com/y2n2vkxd
More Info:
avithrapid.eu
#AVITHRAPID
in Hamburg. Check out our short video!
tinyurl.com/y2n2vkxd
More Info:
avithrapid.eu
#AVITHRAPID
Toxins from remipede crabs in Mexican cenote caves have pharmacological potential @BReumont @goetheuni @LOEWE_TBG @FraunhoferITMP @EUVENAction @KU_Leuven @UniCologne
...
weiterlesen
Toxins from remipede crabs in Mexican cenote caves have pharmacological potential @BReumont @goetheuni @LOEWE_TBG @FraunhoferITMP @EUVENAction @KU_Leuven @UniCologne
...
weiterlesen
weiterlesen
weiterlesen
Rallybio contributes to promising results in the RLYB212 Phase 1 study—paving the way for transformative therapies in preventing FNAIT, a rare but serious disease that affects newborns.
More Information: linktr.ee/fraunhofer.i...
Rallybio contributes to promising results in the RLYB212 Phase 1 study—paving the way for transformative therapies in preventing FNAIT, a rare but serious disease that affects newborns.
More Information: linktr.ee/fraunhofer.i...